NCT04738942: A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
- State
- Under way
- Phase
- Phase 3
- People
- 56 taking part
- Started
- 4 Jun 2021
- Primary completion
- 30 May 2025
- Arms
- Vedolizumab 300 mg in UC cohort, Vedolizumab 300 mg in CD cohort
- Results
- Posted on the registry
- 4 Feb 2021: Trial registered
- 4 Jun 2021: Trial started
- 15 Jun 2026: Trial results posted